DelveInsight’s, “ Idiopathic Pulmonary Fibrosis Pipeline Insights 2025 ” report provides comprehensive insights about 80+ ...

The study found through multi-omics integration analysis that rheumatoid arthritis is a causal factor of idiopathic pulmonary ...

BEACON-IPF close out activities continuePreviously announced workforce and operational realignment largely completePhase 1 ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Kristy Smith says in June she was diagnosed with idiopathic pulmonary fibrosis which caused scarring on the lungs and makes ...

In August 2025, InSilico Medicine Hong Kong Limited announced a clinical trial is to learn about INS018_055 in adults with ...

Contineum Therapeutics has pumped the brakes on two projects, freeing up resources to go full speed ahead in its pursuit of Bristol Myers Squibb in idiopathic pulmonary fibrosis.

Discover Trevi Therapeutics' Q2 2025 progress, featuring groundbreaking CORAL & RIVER trial data, a $204M cash position, and plans for multiple Phase ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

A new AI tool helps predict survival in fibrotic lung disease, outperforming traditional clinical and imaging methods in a study of over 1,200 patients.

A Barrow in Furness family are running a 10K to raise awareness and funds for Action for Pulmonary Fibrosis in memory of shipyard worker ...